HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan

Q: How much expense ratio is charged by HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan?

The expense ratio for HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan, or any other mutual fund, is the yearly fee you pay for managing your investments. As of 19 May 2025, the expense ratio charged by HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan is typically around undefined %. This fee covers fund management, administrative, and other operational costs. It is relatively low compared to actively managed funds, reflecting its direct growth option.

Q: What is the AUM of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan?

As of 19 May 2025, the Assets Under Management (AUM) of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan is approximately ₹1666.3613 crore. The AUM can fluctuate based on market conditions and investor activity. It indicates the total value of assets managed by the fund.

Q: What is the NAV of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan?

The Net Asset Value (NAV) of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan is updated daily and reflects the per-unit value of the fund's assets. As of 19 May 2025 , the NAV is around undefined per unit, but this value might change based on market performance and fund holdings.

Q: What is the PE and PB ratio of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan?

The PE ratio for HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan is 47.79 and the PB ratio is 7.41. The PE ratio is calculated by dividing the market price by the earnings per share, whereas the PB ratio is calculated by dividing the stock price by the book value per share.

Q: What is the exit load of HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan?

The exit load for HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan is undefined% if units are redeemed within 30 days from the date of investment. After this period, no exit load is applicable. This fee is charged to discourage short-term trading and ensure long-term investment.

Equity

NAV

₹ 16.54

CAGR (3 Years)

AUM (Cr)

₹ 1,666.36

Risk

Very High Risk

About HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan

To provide long-term capital appreciation by investing predominantly in equity and equity related s securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.